SL-325 Phase 1 Supports Longer-Interval DR3 Blockade

Company: Shattuck Labs · Event Type: Clinical/Regulatory Signal · Product/Asset: SL-325 · Subject: Inflammatory Disease · Event Date: August 11, 2026 Summary Shattuck Labs reported Phase 1 healthy-volunteer results for SL-325, a monoclonal antibody that blocks the TL1A receptor DR3. The company observed 3.7% anti-drug-antibody…